[go: up one dir, main page]

AT514675A3 - Herstellung von faktor h (fh) und fh-derivaten aus plasma - Google Patents

Herstellung von faktor h (fh) und fh-derivaten aus plasma Download PDF

Info

Publication number
AT514675A3
AT514675A3 ATA50852/2014A AT508522014A AT514675A3 AT 514675 A3 AT514675 A3 AT 514675A3 AT 508522014 A AT508522014 A AT 508522014A AT 514675 A3 AT514675 A3 AT 514675A3
Authority
AT
Austria
Prior art keywords
publication
date
category
importance
considered
Prior art date
Application number
ATA50852/2014A
Other languages
English (en)
Other versions
AT514675B1 (de
AT514675A2 (de
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of AT514675A2 publication Critical patent/AT514675A2/de
Publication of AT514675A3 publication Critical patent/AT514675A3/de
Application granted granted Critical
Publication of AT514675B1 publication Critical patent/AT514675B1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung stellt Zusammensetzungen und pharmazeutische Formulierungen von aus Plasma erhaltenem Faktor H bereit. Weiters werden Verfahren zur Herstellung von Faktor H Zusammensetzungen und Formulierungen, als auch Verfahren zur Behandlung von Krankheiten, die mit einer Dysfunktion von Faktor H assoziiert sind, bereit gestellt.

Description

852/2014 23.07.2010 (51) Int. Cl.: A61K38/17
C07K 1/14 C07K 14/47 (2006.01) (2006.01) (2006.01) (62) (30)
15.05.2018
Ausscheidung aus A 9249/2010
Priorität:
23.07.2009 US 61/227,968 beansprucht.
(56) Entgegenhaltungen: US 2008318841 A1 WO 2007038995 A1 (71) Patentanmelder:
Baxalta Incorporated 60015 Bannockburn (US) Baxalta GmbH
8152 Glattpark (Opfikon) (CH)
AT 514675 A3 2018-05-15 (54) HERSTELLUNG VON FAKTOR H (FH) UND FH-DERIVATEN AUS PLASMA (57) Die vorliegende Erfindung stellt Zusammensetzungen und pharmazeutische Formulierungen von aus Plasma erhaltenem Faktor H bereit. Weiters werden Verfahren zur Herstellung von Faktor H Zusammensetzungen und Formulierungen, als auch Verfahren zur Behandlung von Krankheiten, die mit einer Dysfunktion von Faktor H assoziiert sind, bereit gestellt.
DVR 0078018
Recherchenbericht zu A 50852/2014
Figure AT514675A3_D0001
Klassifikation des Anmeldungsgegenstands gemäß IPC:
A61K 38/17 (2006.01); C07K1/14 (2006.01); CO7K 14/47 (2006.01)
Klassifikation des Anmeldungsgegenstands gemäß CPC:
A61K 38/17 (2013.01); C07K1/14 (2013.01); CO7K 14/472 (2013.01)
Recherchierter Prüfstoff (Klassifikation):
A61K, C07K
Konsultierte Online-Datenbank:
WPI, EPODOC, Fulltext
Dieser Recherchenbericht wurde zu den am 25.11.2014 eingereichten

Claims (2)

  1. Ansprüchen 1-23 erstellt, rm
    Kategorie*·
    Bezeichnung der Veröffentlichung:
    Ländercode, Veröffentlichungsnummer, Dokumentart (Anmelder), Veröffentlichungsdatum, Textstelle oder Figur soweit erforderlich
    Betreffend
    Anspruch
    A
    A
    US 2008318841 Al (CHTOUROU ABDESSADAR SAMI [FR], MAZURIER CLAUDINE [FR], POULLE MICHEL [FR], CAUVIN BERNADETTE [FR], DHAINAULT FREDERIC [FR]) 25. Dezember 2008 (25.12.2008)
    Absätze [0099] [0100]; Ansprüche 10-16
    WO 2007038995 Al (ZLB BEHRING GMBH [DE], GRONSKI PETER [DE], LICHT CHRISTOPH [DE], HOPPE BERND [DE], ZIPFEL PETER [DE], SKERKA CHRISTINE [DE]) 12. April 2007 (12.04.2007)
    Seite 14, Zeilen 19-22
    1, 2, 4-23
    1, 2, 4-23
    Datum der Beendigung der Recherche: ς t 1 1 Prüfer(in):
  2. 20.10.2017 beite 1 von 1 MOSSER Reinhold
    *) Kategorien der angeführten Dokumente: A Veröffentlichung, die den allgemeinen Stand der Technik definiert.
    X Veröffentlichung von besonderer Bedeutung: der Anmeldungs- P Dokument, das von Bedeutung ist (Kategorien X oder Y), jedoch nach gegenständ kann allein aufgrund dieser Druckschrift nicht als neu bzw. auf dem Prioritätstag der Anmeldung veröffentlicht wurde.
    erfinderischer Tätigkeit beruhend betrachtet werden. E Dokument, das von besonderer Bedeutung ist (Kategorie X), aus dem
    Y Veröffentlichung von Bedeutung: der Anmeldungsgegenstand kann nicht ein „älteres Recht“ hervorgehen könnte (früheres Anmeldedatum, jedoch als auf erfinderischer Tätigkeit beruhend betrachtet werden, wenn die nachveröffentlicht, Schutz ist in Österreich möglich, würde Neuheit in Frage
    Veröffentlichung mit einer oder mehreren weiteren Veröffentlichungen stellen).
    dieser Kategorie in Verbindung gebracht wird und diese Verbindung für & Veröffentlichung, die Mitglied der selben Patentfamilie ist.
    einen Fachmann naheliegend ist.
    1/1
    DVR 0078018
ATA50852/2014A 2009-07-23 2010-07-23 Herstellung von faktor h (fh) und fh-derivaten aus plasma AT514675B1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22796809P 2009-07-23 2009-07-23

Publications (3)

Publication Number Publication Date
AT514675A2 AT514675A2 (de) 2015-02-15
AT514675A3 true AT514675A3 (de) 2018-05-15
AT514675B1 AT514675B1 (de) 2019-05-15

Family

ID=42827367

Family Applications (2)

Application Number Title Priority Date Filing Date
ATA50852/2014A AT514675B1 (de) 2009-07-23 2010-07-23 Herstellung von faktor h (fh) und fh-derivaten aus plasma
ATA9249/2010A AT516600B1 (de) 2009-07-23 2010-07-23 Herstellung von faktor h (fh) und fh-derivaten aus plasma

Family Applications After (1)

Application Number Title Priority Date Filing Date
ATA9249/2010A AT516600B1 (de) 2009-07-23 2010-07-23 Herstellung von faktor h (fh) und fh-derivaten aus plasma

Country Status (3)

Country Link
US (3) US8304524B2 (de)
AT (2) AT514675B1 (de)
WO (1) WO2011011753A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8796430B2 (en) * 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
KR20130093607A (ko) * 2010-07-23 2013-08-22 백스터 인터내셔널 인코포레이티드 혈장으로부터 인터-알파-억제제 단백질 (iaip)의 제조
DK2600812T3 (da) * 2010-08-05 2021-10-18 Forsight Vision4 Inc Apparat til at behandle et øje
IL212911A0 (en) * 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
CA2882317C (en) * 2012-09-26 2021-04-06 Bone Therapeutics S.A. Formulations comprising solvent/detergent-treated plasma and hyaluronic acid for treating musculoskeletal diseases
JP6484215B2 (ja) * 2013-03-14 2019-03-13 バクスアルタ インコーポレイテッド 関節リウマチの治療のためのｈ因子
JP6373963B2 (ja) * 2013-03-14 2018-08-15 バクスアルタ インコーポレイテッド 移植のためのｈ因子
AU2013203048A1 (en) * 2013-03-15 2014-10-02 Baxalta GmbH Isolation of factor h from fraction i paste
AU2013202965B2 (en) * 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
CA2907681C (en) 2013-03-28 2022-11-22 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
CN108495860A (zh) * 2015-09-29 2018-09-04 K·黄 一种从组分iii制备静脉注射免疫球蛋白的方法
US20170232079A1 (en) * 2015-10-06 2017-08-17 Kieu Hoang Method of manufacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
EA039316B1 (ru) * 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
IL282227B2 (en) 2018-10-26 2024-08-01 Alkahest Inc Use of plasma and plasma fractions to improve pain, wound healing and recovery after surgery
ES3035008T3 (en) * 2018-11-27 2025-08-27 Gambro Lundia Ab Preparing an extracorporeal blood treatment apparatus
CN113045634B (zh) * 2019-12-28 2023-04-28 四川远大蜀阳药业有限责任公司 一种补体h因子制备方法
WO2022094340A1 (en) * 2020-10-30 2022-05-05 Gemini Therapeutics Sub, Inc. Methods for treating inflammatory ocular diseases with complement factor h
KR20240154657A (ko) 2022-03-07 2024-10-25 다케다 야쿠힌 고교 가부시키가이샤 임상 인간 igg 제품의 친화도 크로마토그래피 생산
CN119300842A (zh) * 2022-05-02 2025-01-10 武田药品工业株式会社 通过超滤从血浆制备科恩池浓缩物的方法
WO2025068923A2 (en) 2023-09-26 2025-04-03 Takeda Pharmaceutical Company Limited IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA
WO2025253181A1 (en) 2024-06-07 2025-12-11 Takeda Pharmaceutical Company Limited Apparatus and methods for monitoring a polypeptide type concentration in a multi-step biologic production process

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038995A1 (en) * 2005-09-19 2007-04-12 Csl Behring Gmbh Factor h for the treatment of chronic nephropathies and production thereof
US20080318841A1 (en) * 2005-12-07 2008-12-25 Laboratoire Francais Du Fractionnement Et Des Biotechnologies S.A. Method For Preparing a Factor H Concentrate and the Use Thereof in the Form of a Drug

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136094A (en) * 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
PT1221918E (pt) 1999-10-21 2005-06-30 Alcon Inc Administracao de drogas sub-tenon
NZ595305A (en) * 2005-02-14 2013-06-28 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
ES2595059T3 (es) * 2007-03-20 2016-12-27 Csl Behring Gmbh Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038995A1 (en) * 2005-09-19 2007-04-12 Csl Behring Gmbh Factor h for the treatment of chronic nephropathies and production thereof
US20080318841A1 (en) * 2005-12-07 2008-12-25 Laboratoire Francais Du Fractionnement Et Des Biotechnologies S.A. Method For Preparing a Factor H Concentrate and the Use Thereof in the Form of a Drug

Also Published As

Publication number Publication date
AT514675B1 (de) 2019-05-15
AT514675A2 (de) 2015-02-15
US9109044B2 (en) 2015-08-18
AT516600A5 (de) 2016-07-15
US20130102537A1 (en) 2013-04-25
AT516600B1 (de) 2016-07-15
US8822656B2 (en) 2014-09-02
WO2011011753A1 (en) 2011-01-27
US20130303731A1 (en) 2013-11-14
US20110021432A1 (en) 2011-01-27
US8304524B2 (en) 2012-11-06

Similar Documents

Publication Publication Date Title
AT514675A3 (de) Herstellung von faktor h (fh) und fh-derivaten aus plasma
Anil et al. Nano-hydroxyapatite (nHAp) in the remineralization of early dental caries: a scoping review
Butera et al. Home oral care with biomimetic hydroxyapatite vs. conventional fluoridated toothpaste for the remineralization and desensitizing of white spot lesions: Randomized clinical trial
Butera et al. SEM/EDS evaluation of the mineral deposition on a polymeric composite resin of a toothpaste containing biomimetic Zn-carbonate hydroxyapatite (microRepair®) in oral environment: a randomized clinical trial
Al-Haj Husain et al. Clinical performance of partial and full-coverage fixed dental restorations fabricated from hybrid polymer and ceramic CAD/CAM materials: A systematic review and meta-analysis
Ispas et al. Comparative assessment of the functional parameters for metal-ceramic and all-ceramic teeth restorations in prosthetic dentistry—A literature review
Muedra et al. Could the calcium silicate-based sealer presentation form influence dentinal sealing? An in vitro confocal laser study on tubular penetration
AT513369A3 (de) Verfahren zum Erzeugen, Übertragen und Empfangen stereoskopischer Bilder, und zugehörige Geräte
Krishnamoorthy et al. Chlorhexidine for the treatment of peri-implantitis: Is it a benison?
Lan et al. Fracture resistance of monolithic zirconia crowns in implant prostheses in patients with bruxism
Kang et al. Long‐term patient monitoring for clozapine‐induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS?
Ferrari et al. Survival rates of endodontically treated posterior teeth restored with all-ceramic partial-coverage crowns: When systematic review fails
Al-Saleh et al. Marginal misfit of 3d-printed (selective laser sintered), CAD-CAM and lost wax technique cobalt chromium copings with shoulder and chamfer finish lines: An in-vitro study
Gascon et al. The effect of antioxidants on dentin bond strength after application of common endodontic irrigants: a systematic review
Froimovici et al. Fixed full-arch implant-supported restorations: techniques review and proposal for improvement
Im et al. A phenomenological study of suicide attempts in elders
Otake et al. Effect of method of removing caries-affected dentin on the bond strength of composite resin to root canal dentin
Butera et al. Evaluation of the efficacy of low-particle-size toothpastes against extrinsic pigmentations: a randomized controlled clinical trial
Frolo et al. Biomechanical analysis of palateless splinted and unsplinted maxillary implant-supported overdentures: A three-dimensional finite element analysis
Rico-Coderch et al. Influence of CAD/CAM manufacturing technique and implant abutment angulation on loosening of individual screw-retained implant crowns
Enax et al. The Whitening Efficacy of a Hydroxyapatite Toothpaste and a Blue Covarine Toothpaste: A Comparative In Vitro Study
GÖKYAR et al. Bioceramic-Based Root Canal Sealers: A Bibliometric Analysis of the 100 Most-Cited Articles: Methodological Studies.
Tafuri et al. Overlay Preparation Accuracy: An In Vitro Study on the Influence of Magnification and Operator Expertise
Taraszkiewicz-Sulik et al. Two-Year Clinical Performance of Ultra-Thin No-Prep Veneers from 5Y-TZP Zirconia: A Retrospective Study
DE102011005872A1 (de) Verfahren zur Herstellung und Weiterverarbeitung von Zahnersatzteilen

Legal Events

Date Code Title Description
PC Change of the owner

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JP

Effective date: 20210719